8-K: Rhythm Pharmaceuticals Reports Positive Phase 2 Bivamelagon Results for Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals announced positive topline results from its Phase 2 trial of bivamelagon, an oral MC4R agonist, showing statistically significant and clinically meaningful BMI reductions in patients with acquired hypothalamic obesity.

Summary

• Bivamelagon achieved statistically significant and clinically meaningful reductions in body mass index (BMI) at 14 weeks of treatment.
• The 600mg cohort (n=8) showed a -9.3% BMI reduction from baseline (p-value=0.0004).
• The 400mg cohort (n=7) showed a -7.7% BMI reduction from baseline (p-value=0.0002).
• The 200mg cohort (n=6) showed a -2.7% BMI reduction from baseline (p-value=0.0180).
• Patients in the placebo cohort (n=7) experienced a 2.2% BMI increase over 14 weeks.
• A post-hoc analysis indicated bivamelagon's BMI reductions were consistent with those achieved by setmelanotide therapy in similar patient populations at comparable dosing durations.
• Patients reported meaningful reductions in their most hunger scores at 14 weeks: 600mg (n=8) and 400mg (n=6) cohorts achieved a mean reduction greater than 2.8 points on a 10-point scale, while the 200mg arm (n=6) achieved a 2.1 point reduction, and placebo patients reported a 0.8 point increase.
• Bivamelagon demonstrated safety and tolerability results consistent with MC4R agonism and its mechanism of action.
• One patient discontinued therapy due to a serious adverse event (rectal bleeding); most common reported adverse events were mild diarrhea and nausea.
• Mild, localized hyperpigmentation was reported in four patients, including one on placebo.
• A total of 27 patients completed the 14-week placebo-controlled portion, with 26 transitioning into the open-label extension and remaining in that portion as of July 7, 2025.

Sentiment

Score: 9

Explanation: The document reports highly positive and statistically significant topline results from a Phase 2 trial for a new drug candidate, bivamelagon, showing clinically meaningful BMI and hunger reductions consistent with an already approved drug. This significantly de-risks the asset and outlines a clear path to Phase 3, indicating strong progress for the company's pipeline.

Positives

• Bivamelagon achieved statistically significant and clinically meaningful BMI reductions across all tested doses in patients with acquired hypothalamic obesity.
• The 600mg and 400mg cohorts demonstrated substantial BMI reductions of -9.3% and -7.7% respectively, at 14 weeks.
• Post-hoc analysis confirmed that bivamelagon's BMI reductions were consistent with those achieved by setmelanotide, Rhythm's approved MC4R agonist, in similar patient populations.
• Patients reported meaningful reductions in hunger scores, a critical symptom of acquired hypothalamic obesity, consistent with the drug's mechanism of action.
• The safety and tolerability profile of bivamelagon was generally consistent with MC4R agonism, with most adverse events being mild or Grade 1.
• A high percentage of patients (26 out of 27 eligible) transitioned into and remained in the open-label extension, indicating good long-term tolerability and patient retention.
• Rhythm plans to request an End-of-Phase 2 meeting with the U.S. FDA and seek scientific advice from the EMA, indicating a clear and positive path towards a Phase 3 trial and potential regulatory approval.
• The company is refining the formulation of bivamelagon into a smaller tablet, potentially improving tolerability for future trials.

Negatives

• One patient discontinued therapy due to a serious adverse event (rectal bleeding) during the placebo-controlled portion of the trial.
• Common adverse events included nausea, diarrhea, vomiting, and headache, although the majority were mild or Grade 1.
• Mild, localized hyperpigmentation was observed in four patients, including one patient in the placebo group.

Risks

• Ability to enroll patients in clinical trials.
• Design and outcome of clinical trials.
• Impact of competition.
• Ability to achieve or obtain necessary regulatory approvals.
• Risks associated with data analysis and reporting.
• Ability to successfully commercialize setmelanotide.
• Liquidity and expenses.
• Ability to retain key employees and consultants, and to attract, retain and motivate qualified personnel.
• General economic conditions.

Future Outlook

Rhythm plans to request an End-of-Phase 2 meeting with the U.S. FDA and seek scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to align on a Phase 3 trial design for bivamelagon in acquired hypothalamic obesity. The company also intends to refine the formulation of bivamelagon to potentially improve tolerability before initiating a Phase 3 trial in 2026.

Management Comments

• "We are excited by these results, which suggest bivamelagon has the potential to treat patients with acquired hypothalamic obesity, and has established an appropriate dose range for future clinical evaluation." David Meeker, M.D., Chair, Chief Executive Officer and President of Rhythm Pharmaceuticals.
• "Unlike in studies evaluating general obesity, once again we observed no placebo effect in this study." David Meeker, M.D.
• "We look forward to engaging with U.S. and European regulatory authorities to seek alignment on a Phase 3 trial design as we continue advancing bivamelagon." David Meeker, M.D.

Industry Context

Acquired hypothalamic obesity is a rare and severe form of obesity resulting from damage to the hypothalamic region of the brain, which disrupts the melanocortin-4 receptor (MC4R) pathway, leading to insatiable hunger (hyperphagia) and rapid weight gain. Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company specializing in rare neuroendocrine diseases, with an existing approved MC4R agonist, setmelanotide (IMCIVREE), for other genetic forms of obesity. The positive Phase 2 results for bivamelagon reinforce the therapeutic potential of MC4R agonism for these conditions and expand Rhythm's pipeline in a niche market with significant unmet medical need. The estimated prevalence of acquired hypothalamic obesity is 5,000-10,000 people in the U.S., 5,000-8,000 in Japan, and 3,500-10,000 in the E.U., indicating a notable market opportunity.

Comparison to Industry Standards

• Bivamelagon's BMI reductions were consistent with those achieved by setmelanotide therapy in similar patient populations at comparable dosing durations, as shown in a post-hoc analysis.
• Bivamelagon achieved -8.8% and -10.1% mean BMI reductions in the 400mg (n=6) and 600mg (n=7) cohorts, respectively, at 14 weeks.
• This compares favorably to setmelanotide's -9.7% and -10.5% mean BMI reductions observed in a pooled patient population (n=59; n=64) from its Phase 2 and Phase 3 trials at 12 weeks and 16 weeks, respectively, for compliant patients not on concomitant GLP1 therapy.
• Patients on bivamelagon also reported meaningful reductions in hunger scores, which aligns with observations from past setmelanotide trials and the expected effects of MC4R agonism.

Stakeholder Impact

• Shareholders: The positive Phase 2 results for a key pipeline asset could significantly enhance the company's valuation and future revenue potential, likely leading to increased share price.
• Patients: The promising results offer hope for a new, effective oral treatment option for acquired hypothalamic obesity, addressing a significant unmet medical need and improving quality of life.
• Employees: Positive clinical trial outcomes can boost morale, validate research efforts, and potentially lead to further investment in R&D and career opportunities.
• Regulatory Authorities: The company will engage with the FDA and EMA to discuss Phase 3 trial design, indicating a collaborative path towards potential market approval.
• Competitors: The success of bivamelagon could intensify competition in the rare neuroendocrine disease and obesity treatment space, particularly for MC4R agonists.

Next Steps

• Request an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA).
• Seek scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
• Refine the formulation of bivamelagon potentially to improve tolerability.
• Initiate Phase 3 trial to evaluate bivamelagon in hypothalamic obesity in 2026.
• Present results from this trial in a poster and data from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide at The Endocrine Society's Annual Meeting (ENDO 2025) on July 12, 2025, in San Francisco.

Key Dates

Recommendation

Keywords

Rhythm Pharmaceuticals, bivamelagon, acquired hypothalamic obesity, MC4R agonist, Phase 2 trial, BMI reduction, hunger, setmelanotide, rare neuroendocrine diseases, biopharmaceutical, clinical trial results, FDA, EMA